Cargando…

Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine

OBJECTIVE: To study the feasibility of multimodal neuroimaging in mild to moderate Alzheimer disease (AD) and to estimate the size of possible treatment effects of memantine on potential functional, structural and metabolic biomarkers of disease progression. METHODS: In this randomised, double-blind...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt, R, Ropele, S, Pendl, B, Ofner, P, Enzinger, C, Schmidt, H, Berghold, A, Windisch, M, Kolassa, H, Fazekas, F
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2008
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582338/ https://www.ncbi.nlm.nih.gov/pubmed/18586865 http://dx.doi.org/10.1136/jnnp.2007.141648

Ejemplares similares

Multimodal assessment of white matter tracts in amyotrophic lateral sclerosis
por: Borsodi, Florian, et al.
Publicado: (2017)

Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease
por: Tampi, Rajesh R, et al.
Publicado: (2007)

Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine
por: Zarra, Julio, et al.
Publicado: (2010)

Study of the Neuroprotective Effects of Memantine in Patients with Mild to Moderate Ischemic Stroke
por: Kafi, Hamidreza, et al.
Publicado: (2014)

Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer’s disease in the Netherlands
por: Hoogveldt, Bart, et al.
Publicado: (2011)

Brain Activity Changes in Cognitive Networks in Relapsing-Remitting Multiple Sclerosis – Insights from a Longitudinal fMRI Study
por: Loitfelder, Marisa, et al.
Publicado: (2014)

An Open-Label Exploratory Study with Memantine: Correlation between Proton Magnetic Resonance Spectroscopy and Cognition in Patients with Mild to Moderate Alzheimer's Disease
por: Gordon, Marc L., et al.
Publicado: (2012)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
por: Puangthong, Umamon, et al.
Publicado: (2009)

Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)
por: Knapp, Martin, et al.
Publicado: (2016)

Update on the use of memantine in Alzheimer’s disease
por: van Marum, Robert J
Publicado: (2009)

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
por: Jones, Rob, et al.
Publicado: (2009)

Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer's Disease: A Review of Clinical Trials
por: Molino, Ivana, et al.
Publicado: (2013)

Synthesis and Comparison of the Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s Disease
por: Rive, Benoît, et al.
Publicado: (2013)

Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer's disease: A clinical trial
por: Zhou, Tiantian, et al.
Publicado: (2019)

Memantine Derivatives as Multitarget Agents in Alzheimer’s Disease
por: Marotta, Giambattista, et al.
Publicado: (2020)

Metabolic Syndrome, Brain Magnetic Resonance Imaging, and Cognition
por: Cavalieri, Margherita, et al.
Publicado: (2010)

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
por: Deardorff, William James, et al.
Publicado: (2016)

Combined application of tenuigenin and β-asarone improved the efficacy of memantine in treating moderate-to-severe Alzheimer’s disease
por: Chang, Wenguang, et al.
Publicado: (2018)

Virtual Therapy with the NMDA Antagonist Memantine in Hippocampal Models of Moderate to Severe Alzheimer’s Disease, In Silico Trials
por: Świetlik, Dariusz, et al.
Publicado: (2022)

Gray Matter Covariance Networks as Classifiers and Predictors of Cognitive Function in Alzheimer’s Disease
por: Wagner, Fabian, et al.
Publicado: (2020)

Memantine-induced Myoclonus in a Patient with Alzheimer Disease
por: Murgai, Aditya A., et al.
Publicado: (2015)

Memantine prodrug as a new agent for Alzheimer’s Disease
por: Sestito, Simona, et al.
Publicado: (2019)

Abnormalities of Resting State Functional Connectivity Are Related to Sustained Attention Deficits in MS
por: Loitfelder, Marisa, et al.
Publicado: (2012)

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013)

Memantine Attenuates Alzheimer’s Disease-Like Pathology and Cognitive Impairment
por: Wang, Xiaochuan, et al.
Publicado: (2015)

Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer’s disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity
por: Koola, Maju Mathew, et al.
Publicado: (2018)

The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, double-blind, placebo-controlled trial
por: Chen, Christopher L.H., et al.
Publicado: (2019)

Serum neurofilament light levels in normal aging and their association with morphologic brain changes
por: Khalil, Michael, et al.
Publicado: (2020)

Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

Effect of memantine, an anti-Alzheimer’s drug, on rodent microglial cells in vitro
por: Murakawa-Hirachi, Toru, et al.
Publicado: (2021)

Characteristics of falls in mild and moderate Alzheimer’s disease
por: Kato-Narita, Eliane Mayumi, et al.
Publicado: (2009)

Memantine treatment for Japanese patients with moderate to severe Alzheimer’s disease: a meta-analysis of double-blind, randomized, placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2018)

Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer’s Disease in the United States: A Cost-Effectiveness Analysis(1)
por: Yunusa, Ismaeel, et al.
Publicado: (2021)

Erratum to: Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer’s Disease in the United States: A Cost-Effectiveness Analysis
Publicado: (2021)

Are morphologic features of recent small subcortical infarcts related to specific etiologic aspects?
por: Eppinger, Sebastian, et al.
Publicado: (2019)

Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
por: Burstein, Aaron H, et al.
Publicado: (2014)

Pharmacodynamics of Memantine: An Update
por: Rammes, G, et al.
Publicado: (2008)

Baseline white matter hyperintensities affect the course of cognitive function after small vessel disease‐related stroke: a prospective observational study
por: Fruhwirth, V., et al.
Publicado: (2020)

Predictive value of different conventional and non-conventional MRI-parameters for specific domains of cognitive function in multiple sclerosis
por: Pinter, Daniela, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1oeb47ov7h3r9qcfgu3c1a4jd8